Debt to Capital Ratio: A measurement of a company's financial leverage, calculated as the company's long-term debt divided by its total capital. Calculated as: Total Long-Term Debt / (Total Long-Term Debt + Shareholders Equity)
CRISPR Therapeutics AG (CRSP) had Debt to Capital Ratio of 0.25 for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$10.18M |
|
$-91.15M |
|
-- |
|
$10.18M |
|
$127.45M |
|
$-117.27M |
|
$27.07M |
|
$-90.19M |
|
$-90.19M |
|
$-91.15M |
|
$-91.15M |
|
$-91.15M |
|
$-91.15M |
|
$-117.27M |
|
$-112.99M |
|
96.51M |
|
96.51M |
|
$-0.94 |
|
$-0.94 |
|
| Balance Sheet Financials | |
$2.37B |
|
$108.07M |
|
$279.00M |
|
$2.65B |
|
$132.90M |
|
$586.20M |
|
$771.32M |
|
$904.22M |
|
$1.75B |
|
$1.75B |
|
$1.75B |
|
96.66M |
|
| Cash Flow Statement Financials | |
$-192.40M |
|
$-466.40M |
|
$599.09M |
|
$359.08M |
|
$299.34M |
|
$-59.73M |
|
$33.64M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
17.85 |
|
-- |
|
-- |
|
|
Debt to Capital Ratio |
0.25 |
0.34 |
|
100.00% |
|
-1151.84% |
|
-1151.84% |
|
-- |
|
-885.91% |
|
-895.33% |
|
$-193.55M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-5.22% |
|
-5.22% |
|
-3.44% |
|
-3.91% |
|
$18.07 |
|
$-2.01 |
|
$-1.99 |
|